.jpg)
CANCER IMMUNOTHERAPY REINVENTED.
ACTIVATE INNATE AND ADAPTIVE
IMMUNE RESPONSES.
SYSTEMICALLY.
SYNERGISTICALLY.
SAFELY.
DECOY BIOSYSTEMS
WHAT
Decoy Biosystems is a private, JLABS San Diego-based, biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for >90% of all cancer deaths. We are developing a novel, multi-targeted product that safely activates both innate and adaptive anti-tumor and anti-viral immune responses.
WHY
Current approved cancer immunotherapy products are only capable of curing a small percentage of metastatic or advanced cancer patients. Efficient or high percentage cures will require solutions to two challenges.
First--Tumors evade normal immune surveillance by producing direct immune suppressors, as well as by attracting and stimulating proliferation of negative regulatory immune cells. Fortunately, a number of agents are available which have the potential to reverse tumor-mediated suppression.
The second, unsolved challenge relates to the need for activation of both innate and adaptive immune pathways. When activated, the cellular components of both our innate and adaptive immune systems can kill tumor cells. In addition, activation of the innate system acts as a bridge to promote the most effective activation of the adaptive system. Thus, activation of both systems provides the best chance to produce durable anti-tumor responses. Unfortunately, activation of both systems can lead to excessive toxicity. An effective and safe method to simultaneously activate both systems has not been identified...until now.
HOW
Decoy has taken advantage of the world’s first immunotherapy, developed in 1894, to produce a systemically administered, killed and intact, non-pathogenic bacterial product that is able to synergistically and safely activate both innate and adaptive anti-tumor immune responses. Decoy’s broadly patented technology, including our first clinical candidate, Decoy20, produces significant pre-clinical single agent activity against orthotopic colorectal and metastatic pancreatic carcinoma, and synergizes with existing immunotherapies, including anti-PD-1 checkpoint therapy, targeted therapy and low-dose chemotherapy, to eradicate established colorectal and hepatocellular carcinoma and non-Hodgkin’s lymphoma tumors, with induction of innate and adaptive immunological memory. These initial target indications make up 20% of yearly world-wide cancer cases and 24% of cancer deaths, representing a $25 billion market. Decoy technology is also active against chronic hepatitis B virus (HBV) and HIV infection in standard pre-clinical models. Decoy20 will enter clinical development for cancer and hepatocellular carcinoma-associated HBV in Q1 of 2021.
Back to the Future Cancer Immunotherapy
DECOY BIOSYSTEMS
WHAT
Decoy Biosystems is a private, JLABS San Diego-based, biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for >90% of all cancer deaths. We are developing a novel, multi-targeted product that safely activates both innate and adaptive anti-tumor and anti-viral immune responses.
WHY
Current approved cancer immunotherapy products are only capable of curing a small percentage of metastatic or advanced cancer patients. Efficient or high percentage cures will require solutions to two challenges.
First--Tumors evade normal immune surveillance by producing direct immune suppressors, as well as by attracting and stimulating proliferation of negative regulatory immune cells. Fortunately, a number of agents are available which have the potential to reverse tumor-mediated suppression.
The second, unsolved challenge relates to the need for activation of both innate and adaptive immune pathways. When activated, the cellular components of both our innate and adaptive immune systems can kill tumor cells. In addition, activation of the innate system acts as a bridge to promote the most effective activation of the adaptive system. Thus, activation of both systems provides the best chance to produce durable anti-tumor responses. Unfortunately, activation of both systems can lead to excessive toxicity. An effective and safe method to simultaneously activate both systems has not been identified...until now.
HOW
Decoy has taken advantage of the world’s first immunotherapy, developed in 1894, to produce a systemically administered, killed and intact, non-pathogenic bacterial product that is able to synergistically and safely activate both innate and adaptive anti-tumor immune responses. Decoy’s broadly patented technology, including our first clinical candidate, Decoy20, produces significant pre-clinical single agent activity against orthotopic colorectal and metastatic pancreatic carcinoma, and synergizes with existing immunotherapies, including anti-PD-1 checkpoint therapy, targeted therapy and low-dose chemotherapy, to eradicate established colorectal and hepatocellular carcinoma and non-Hodgkin’s lymphoma tumors, with induction of innate and adaptive immunological memory. These initial target indications make up 20% of yearly world-wide cancer cases and 24% of cancer deaths, representing a $25 billion market. Decoy technology is also active against chronic hepatitis B virus (HBV) and HIV infection in standard pre-clinical models. Decoy20 will enter clinical development for cancer and hepatocellular carcinoma-associated HBV in Q1 of 2021.
CONTACT US
Decoy Biosystems, Inc.
JLABS
3210 Merryfield Row
San Diego, CA 92121
(858) 492-0485